(Q36082082)

12 August 2017

1 reference

title

Sirolimus: a new option in transplantation (English)

1 reference

12 August 2017

1 reference

Alfredo Mota

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

Expert Opinion on Pharmacotherapy

12 August 2017

published in

1 reference

12 August 2017

volume

6

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

479-487

1 reference

Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.479

Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.479

Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.479

Cyclosporin A in patients receiving renal allografts from cadaver donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.479

Chronic renal failure after transplantation of a nonrenal organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.479

Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.479

Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.479

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.479

Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.479

The natural history of chronic allograft nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.479

Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.479

Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.479

Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.479

Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation1,2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.479

Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.479

Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.479

Post-transplant renal function in the first year predicts long-term kidney transplant survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.479

De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.479

Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.479

Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.479

Rapamycin in transplantation: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.479

Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.3.479

21 January 2018

Identifiers

DOI

10.1517/14656566.6.3.479

1 reference

12 August 2017

1 reference